SCHEMBL18920280

SCHEMBL18920280

CCC=CCC=CCC=CCC=CCCSC(C)(C)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 4/20 0.51
ALDH1A1 P00352 7/20 0.50
CYP19A1 P11511 4/20 0.50
MAPT P10636 4/20 0.50
PPARG P37231 3/20 0.50
OXER1 Q8TDS5 3/20 0.50
RXRA P19793 2/20 0.50
FFAR1 O14842 2/20 0.50
F7 P08709 3/20 0.47
F3 P13726 3/20 0.47
PPARA Q07869 3/20 0.47
KMT2A Q03164 2/20 0.47
PPARD Q03181 2/20 0.47
ADORA3 P0DMS8 2/20 0.47
NR1I2 O75469 2/20 0.45
PTGS2 P35354 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
LMNA P02545 1/20 0.45
PLA2G1B P04054 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18920278 1.00 PTGS1 (0.51) PTGS1ALDH1A1CYP19A1MAPTPPARG
SCHEMBL1551789 0.89 ALDH1A1 (0.53) PTGS1ALDH1A1CYP19A1MAPTPPARG
SCHEMBL1551784 0.89 ALDH1A1 (0.53) PTGS1ALDH1A1CYP19A1MAPTPPARG
SCHEMBL18944610 0.85 ALDH1A1 (0.54) PTGS1ALDH1A1CYP19A1MAPTPPARG
SCHEMBL18944751 0.85 ALDH1A1 (0.54) PTGS1ALDH1A1CYP19A1MAPTPPARG
SCHEMBL24829879 0.85 ALDH1A1 (0.49) PTGS1ALDH1A1CYP19A1MAPTPPARG
SCHEMBL3419336 0.81 PTGS1 (0.50) PTGS1ALDH1A1CYP19A1MAPTPPARG
SCHEMBL3419343 0.81 PTGS1 (0.50) PTGS1ALDH1A1CYP19A1MAPTPPARG
SCHEMBL18944632 0.81 ADORA3 (0.49) PTGS1ALDH1A1CYP19A1MAPTPPARG
SCHEMBL18944633 0.79 PTGS1 (0.44) PTGS1ALDH1A1CYP19A1MAPTPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3383380-B1 LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE BIOZEP AS (NO) 2023-01-04 EP disclosed
US-20180346408-A1 LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE BIOZEP AS (NO) 2018-12-06 US disclosed
EP-3383380-A1 LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE Biozep AS (NO) 2018-10-10 EP disclosed
WO-2017093732-A1 LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE BIOZEP AS (NO) 2017-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180346408-A1 LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE NR1H2, NR1H3, APOB PTGS1 245/4885ALDH1A1 618/4885CYP19A1 1093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.